Business Context and Reporting Period
This Form 8-K was filed by Lucid Diagnostics Inc. (LUCD) on January 30, 2024, reporting events occurring on January 26, 2024. The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific equity transaction.
- Transaction Value: $4,675,256 in fees and reimbursements.
- Shares Issued: 3,331,771 shares of common stock.
- Counterparty: PAVmed Inc. (Parent Company).
Material Changes
The material change reported is the unregistered sale of equity securities to the parent company, PAVmed Inc. Under a Management Services Agreement (MSA) and a Payroll and Benefit Expense Reimbursement Agreement (PBERA), PAVmed elected to receive payment for services and expenses accrued between October 1, 2022, and December 31, 2022, in the form of common stock rather than cash.
Outlook, Risks, and Management Commentary
Management notes that the issuance of 3,331,771 shares to PAVmed is equal to the aggregate number of shares PAVmed will distribute to its own stockholders on or prior to February 15, 2024. The filing does not contain forward-looking guidance, risk factors, or commentary on future operations beyond this specific transaction.
Investor Verification Checklist
- Verify the impact of the 3,331,771 new shares on total outstanding share count and potential dilution.
- Confirm the distribution timeline of these shares to PAVmed stockholders (on or before February 15, 2024).
- Review the terms of the MSA and PBERA to understand future potential for stock-based compensation or expense reimbursement.
- Check subsequent filings for the actual distribution of shares to PAVmed stockholders.